| Assessment Status |
Submission Withdrawn. See Pegvaliase (Palynziq®) HTA ID: 21057 |
| HTA ID |
20001 |
| Drug |
Pegvaliase |
| Brand |
Palynziq® |
| Indication |
For the treatment of patients with phenylketonuria aged 16 years and older who have inadequate blood phenylalanine control (blood phenylalanine levels greater than 600 micromol/l) despite prior management with available treatment options. |
| Rapid review commissioned |
13/01/2020 |
| Rapid review completed |
24/02/2020 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pegvaliase compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
26/02/2020 |
| Pre-submission consultation with Applicant |
27/04/2020 |
| Full submission received from Applicant |
02/11/2020 |
| Preliminary review sent to Applicant |
21/12/2020 |
| Full re-submission received from Applicant |
18/11/2021 |
